134 related articles for article (PubMed ID: 24533805)
1. Davunetide: Peptide therapeutic in neurological disorders.
Magen I; Gozes I
Curr Med Chem; 2014; 21(23):2591-8. PubMed ID: 24533805
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP).
Magen I; Gozes I
Neuropeptides; 2013 Dec; 47(6):489-95. PubMed ID: 24210139
[TBL] [Abstract][Full Text] [Related]
3. Microtubules (tau) as an emerging therapeutic target: NAP (davunetide).
Gozes I
Curr Pharm Des; 2011; 17(31):3413-7. PubMed ID: 21902667
[TBL] [Abstract][Full Text] [Related]
4. Protection against tauopathy by the drug candidates NAP (davunetide) and D-SAL: biochemical, cellular and behavioral aspects.
Shiryaev N; Pikman R; Giladi E; Gozes I
Curr Pharm Des; 2011; 17(25):2603-12. PubMed ID: 21728979
[TBL] [Abstract][Full Text] [Related]
5. Davunetide: a review of safety and efficacy data with a focus on neurodegenerative diseases.
Morimoto BH; Fox AW; Stewart AJ; Gold M
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):483-502. PubMed ID: 23971871
[TBL] [Abstract][Full Text] [Related]
6. Microtubules, schizophrenia and cognitive behavior: preclinical development of davunetide (NAP) as a peptide-drug candidate.
Gozes I
Peptides; 2011 Feb; 32(2):428-31. PubMed ID: 21050875
[TBL] [Abstract][Full Text] [Related]
7. NAP (davunetide) provides functional and structural neuroprotection.
Gozes I
Curr Pharm Des; 2011; 17(10):1040-4. PubMed ID: 21524250
[TBL] [Abstract][Full Text] [Related]
8. VIP/PACAP-Based Drug Development: The ADNP/NAP-Derived Mirror Peptides SKIP and D-SKIP Exhibit Distinctive
Sragovich S; Amram N; Yeheskel A; Gozes I
Front Cell Neurosci; 2019; 13():589. PubMed ID: 31992971
[TBL] [Abstract][Full Text] [Related]
9. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model.
Vulih-Shultzman I; Pinhasov A; Mandel S; Grigoriadis N; Touloumi O; Pittel Z; Gozes I
J Pharmacol Exp Ther; 2007 Nov; 323(2):438-49. PubMed ID: 17720885
[TBL] [Abstract][Full Text] [Related]
10. D-SAL and NAP: Two Peptides Sharing a SIP Domain.
Gozes I; Sragovich S; Schirer Y; Idan-Feldman A
J Mol Neurosci; 2016 Jun; 59(2):220-31. PubMed ID: 26816081
[TBL] [Abstract][Full Text] [Related]
11. Davunetide improves spatial learning and memory in Alzheimer's disease-associated rats.
Zhang J; Wei SY; Yuan L; Kong LL; Zhang SX; Wang ZJ; Wu MN; Qi JS
Physiol Behav; 2017 May; 174():67-73. PubMed ID: 28257938
[TBL] [Abstract][Full Text] [Related]
12. Novel tubulin and tau neuroprotective fragments sharing structural similarities with the drug candidate NAP (Davuentide).
Gozes I; Iram T; Maryanovsky E; Arviv C; Rozenberg L; Schirer Y; Giladi E; Furman-Assaf S
J Alzheimers Dis; 2014; 40 Suppl 1():S23-36. PubMed ID: 24503616
[TBL] [Abstract][Full Text] [Related]
13. A novel davunetide (NAPVSIPQQ to NAPVSIPQE) point mutation in activity-dependent neuroprotective protein (ADNP) causes a mild developmental syndrome.
Gozes I; Shazman S
Eur J Neurosci; 2023 Jul; 58(2):2641-2652. PubMed ID: 36669790
[TBL] [Abstract][Full Text] [Related]
14. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy.
Ivashko-Pachima Y; Sayas CL; Malishkevich A; Gozes I
Mol Psychiatry; 2017 Sep; 22(9):1335-1344. PubMed ID: 28115743
[TBL] [Abstract][Full Text] [Related]
15. The cytoskeleton as a drug target for neuroprotection: the case of the autism- mutated ADNP.
Gozes I
Biol Chem; 2016 Mar; 397(3):177-84. PubMed ID: 25955282
[TBL] [Abstract][Full Text] [Related]
16. NAP (Davunetide): The Neuroprotective ADNP Drug Candidate Penetrates Cell Nuclei Explaining Pleiotropic Mechanisms.
Ganaiem M; Gildor ND; Shazman S; Karmon G; Ivashko-Pachima Y; Gozes I
Cells; 2023 Sep; 12(18):. PubMed ID: 37759476
[TBL] [Abstract][Full Text] [Related]
17. NAP, a peptide derived from the activity-dependent neuroprotective protein, modulates macrophage function.
Quintana FJ; Zaltzman R; Fernandez-Montesinos R; Herrera JL; Gozes I; Cohen IR; Pozo D
Ann N Y Acad Sci; 2006 Jul; 1070():500-6. PubMed ID: 16888216
[TBL] [Abstract][Full Text] [Related]
18. NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia.
Merenlender-Wagner A; Pikman R; Giladi E; Andrieux A; Gozes I
Peptides; 2010 Jul; 31(7):1368-73. PubMed ID: 20417241
[TBL] [Abstract][Full Text] [Related]
19. Activity-dependent neuroprotective protein (ADNP)-derived peptide (NAP) ameliorates hypobaric hypoxia induced oxidative stress in rat brain.
Sharma NK; Sethy NK; Meena RN; Ilavazhagan G; Das M; Bhargava K
Peptides; 2011 Jun; 32(6):1217-24. PubMed ID: 21453737
[TBL] [Abstract][Full Text] [Related]
20. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport.
Jouroukhin Y; Ostritsky R; Assaf Y; Pelled G; Giladi E; Gozes I
Neurobiol Dis; 2013 Aug; 56():79-94. PubMed ID: 23631872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
